← Russell 3000 cross-section

GEHC GE HealthCare Technologies Inc.

Trailing twelve months to 2026-03-31 · as filed 2026-04-29, not restated
Healthcare

Scale

Market cap
$33.1bn
Revenue TTM
$21.0bn
Net income TTM
$1.9bn
Free cash flow
$1.5bn
Composite score
59.0
Sector rank
#316

Valuation

P / E
17.3
EV / EBITDA
12.6
EV / sales
2.0
FCF yield
4.59%
Earnings yield vs 10-yr
1.04pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
9.1%
EBITDA margin
15.5%
ROE
17.9%
ROIC
14.3%
Revenue growth
6.0%

Insider activity, last 90 days

Net open-market
$0.00m
Buyers
0
Sellers
0

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

SUMMARY OF KEY PERFORMANCE MEASURES Management reviews and analyzes several key performance measures including Total revenues, Operating income, Net income attributable to GE HealthCare, Earnings per share, and Cash from (used for) operating activities. For the three months ended June 30, 2026 Total revenues were $5,295 million, growing 5.7% as reported and 3.5% organically*. Sales of products increased 4.7% or $153 million primarily driven by strong growth in PDx and AIS revenues, partially offset by declines in PCS revenues. Sales of services increased 7.7% or $135 million primarily driven by the acquisition of Intelerad and growth in new and existing customer contractual agreements. …GE HealthCare Technologies Inc., 10-Q, period ended 2026-06-30, filed 2026-07-29

Read the full passage →